March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Autoantibodies Against Oxidized LDL In Diabetic Retinopathy
Satu Vavuli; Tuire Salonurmi; Sirpa Loukovaara; Markku J. Savolainen; Johanna Liinamaa
Author Affiliations & Notes
  • Satu Vavuli
    Institute of Clinical Medicine,
    University of Oulu, Oulu, Finland
  • Tuire Salonurmi
    Clinical Research Center, Dept. of Internal Medicine, Institute of Clinical Medicine,
    University of Oulu, Oulu, Finland
  • Sirpa Loukovaara
    Dept. of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland
  • Markku J. Savolainen
    Clinical Research Center, Dept. of Internal Medicine, Institute of Clinical Medicine,
    University of Oulu, Oulu, Finland
  • Johanna Liinamaa
    Institute of Clinical Medicine, Dept. of Ophthalmology,
    University of Oulu, Oulu, Finland
  • Footnotes
    Commercial Relationships  Satu Vavuli, None; Tuire Salonurmi, None; Sirpa Loukovaara, None; Markku J. Savolainen, None; Johanna Liinamaa, None
  • Footnotes
    Support  Finnish Eye Foundation
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2429. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Autoantibodies Against Oxidized LDL In Diabetic Retinopathy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Satu Vavuli, Tuire Salonurmi, Sirpa Loukovaara, Markku J. Savolainen, Johanna Liinamaa; Autoantibodies Against Oxidized LDL In Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2429.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Oxidized LDL (ox-LDL) has cytotoxic and immunogenic effects and might therefore play a role in the development of diabetic retinopathy. The purpose of this study was to investigate the role of oxidized LDL and autoantibodies against ox-LDL in diabetic retinopathy.

Methods: : The study population consisted of 229 diabetic patients with clinically moderate to severe diabetic retinopathy (DR group) and 106 diabetic patients with no clinical retinopathy (DC group). In addition, we had 139 non-diabetic patients (C group) as controls. The diabetes duration was at least 10 years in the DC group. Plasma samples were taken after an overnight fast and stored after centrifugation at -70°C. Plasma IgG, IgM and IgA class autoantibody titers to copper oxidized LDL (CuOx-LDL) and malonidialdehyde oxidized LDL (MDAOx-LDL) were measured with chemiluminescence ELISA.

Results: : The DR and DC groups did not differ in age, sex, diabetes type or diabetes duration. The mean IgM titers for CuOx-LDL and MDAOx-LDL were lower for diabetics, but did not differ significantly between DR and DC. The IgM(CuOx-LDL) titers were 4277 (7191), 4152 (2952) and 6714 (10221) and IgM(MDAOx-LDL) titers 3316 (4440), 3536 (2933) and 4258 (3577), for DR, DC and C groups, respectively. IgG(CuOx-LDL) titers were 3476 (3721), 3667 (3361) and 3263 (3778), and IgG(MDAOx-LDL) titers 6827 (5397), 7177 (5056) and 7177 (5056), for DR, DC and C groups, respectively. According to diabetes type the titers in DR and DC were: IgM(CuOx-LDL) 3684 (3566) and 4613 (2910), respectively, for type 1 (p=0.116) and 4796 (9250) and 3740 (2955), respectively, for type 2 (p=0.406). IgG(CuOx-LDL) titers were 3775(4197) and 3097 (2617) for type 1 (p=0.301) and 3296 (3363) and 4177 (3860) for type 2 (p=0.129) for DR and DC, respectively. The effect on MDAOx-LDL titers was similar than for IgG titers. IgA titers against both CuOx-LDL and MDA-LDL were very low.

Conclusions: : IgG, IgA and IgM autoantibodies against ox-LDL did not differ significantly between DR and DC. However, the diabetes type in DR has impact on autoantibody titers, since in type 2 diabetics the IgM/IgG ratio was higher than in type 1 diabetics.

Keywords: diabetic retinopathy • inflammation • lipids 
© 2012, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept